
Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter. In Q3, Neurocrine Biosciences earned $22.50 million and total sales reached $296.00 million.